[go: up one dir, main page]

PE20110407A1 - Composicion farmaceutica que comprende una sal de estroncio, vitamina d y una ciclodextrina - Google Patents

Composicion farmaceutica que comprende una sal de estroncio, vitamina d y una ciclodextrina

Info

Publication number
PE20110407A1
PE20110407A1 PE2010001074A PE2010001074A PE20110407A1 PE 20110407 A1 PE20110407 A1 PE 20110407A1 PE 2010001074 A PE2010001074 A PE 2010001074A PE 2010001074 A PE2010001074 A PE 2010001074A PE 20110407 A1 PE20110407 A1 PE 20110407A1
Authority
PE
Peru
Prior art keywords
strontium
vitamin
cyclodextrin
pharmaceutical composition
beta
Prior art date
Application number
PE2010001074A
Other languages
English (en)
Inventor
Gilles Briault
Xavier Quenault
Cecile Poirier
Jean-Manuel Pean
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41719206&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20110407(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Servier Lab filed Critical Servier Lab
Publication of PE20110407A1 publication Critical patent/PE20110407A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/59Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/5939,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40Cyclodextrins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

SE REFIERA A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE: A) SAL DE ESTRONCIO SELECCIONADA DE RANELATO DE ESTRONCIO, MALONATO DE ESTRONCIO, L-ASCORBATO DE ESTRONCIO, GLUTAMATO DE ESTRONCIO, ENTRE OTROS, B) VITAMINA D TAL COMO COLECALCIFEROL EN UNA DOSIFICACION DE 1000 UI, C) BETA-CICLODEXTRINA SUSTITUIDA SELECCIONADA DE HPBCD (HIDROXIPROPIL-BETA.CICLODEXTRINAS), SBECD (SULFOBUTILETER-BETA-CICLODEXTRINAS), ENTRE OTRAS Y D) UNO O VARIOS EXCIPIENTES O VEHICULOS INERTES. LA RELACION MASICA ENTRE LA CANTIDAD DE VITAMINA D Y CICLODEXTRINA ESTA COMPRENDIDA ENTRE 1/40 Y 1/800. DICHA COMPOSICION ESTA EN FORMA DE COMPRIMIDOS PARA TRAGAR, PARA MASTICAR, COMPRIMIDOS EFERVESCENTES O EN FORMA DE GRANULOS PARA SOBRE SIENDO UTILES EN EL TRATAMIENTO DE ENFERMEDADES OSEAS O DE LA ARTROSIS
PE2010001074A 2009-11-27 2010-11-19 Composicion farmaceutica que comprende una sal de estroncio, vitamina d y una ciclodextrina PE20110407A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0905706A FR2953139B1 (fr) 2009-11-27 2009-11-27 Composition pharmaceutique comprenant un sel de strontium, de la vitamine d et une cyclodextrine

Publications (1)

Publication Number Publication Date
PE20110407A1 true PE20110407A1 (es) 2011-07-02

Family

ID=41719206

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2010001074A PE20110407A1 (es) 2009-11-27 2010-11-19 Composicion farmaceutica que comprende una sal de estroncio, vitamina d y una ciclodextrina

Country Status (31)

Country Link
US (1) US20110130370A1 (es)
EP (1) EP2335704A1 (es)
JP (1) JP2011111458A (es)
KR (1) KR101278935B1 (es)
CN (1) CN102078620A (es)
AP (1) AP2010005490A0 (es)
AR (1) AR079160A1 (es)
AU (1) AU2010241527B2 (es)
BR (1) BRPI1004685A2 (es)
CA (1) CA2723119C (es)
CL (1) CL2010001260A1 (es)
CO (1) CO6280058A1 (es)
CU (1) CU20100230A7 (es)
EA (1) EA018460B1 (es)
EC (1) ECSP10010622A (es)
FR (1) FR2953139B1 (es)
GE (1) GEP20135734B (es)
HN (1) HN2010002518A (es)
IL (1) IL209348A0 (es)
MA (1) MA32363B1 (es)
MX (1) MX2010012566A (es)
MY (1) MY158261A (es)
NZ (1) NZ589513A (es)
PE (1) PE20110407A1 (es)
SG (1) SG171542A1 (es)
SV (1) SV2010003744A (es)
TW (1) TW201200136A (es)
UA (1) UA105766C2 (es)
UY (1) UY33039A (es)
WO (1) WO2011064474A1 (es)
ZA (1) ZA201008230B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1993559T1 (sl) 2006-02-03 2017-01-31 Opko Renal, Llc Zdravljenje nezadostnosti in pomanjkanja vitamina D s 25-hidroksivitaminon D2 in 25-hidroksivitaminom D3
DK3357496T3 (da) 2006-06-21 2020-05-11 Opko Ireland Global Holdings Ltd Terapi ved brug af vitamin d-repletteringsmiddel og vitamin d-hormonsubstitutionsmiddel
PT2148661E (pt) 2007-04-25 2013-03-06 Proventiv Therapeutics Llc Composições orais de libertação controlada compreendendo um composto de vitamina d e veículo ceroso
PT2148684E (pt) 2007-04-25 2013-04-19 Cytochroma Inc Método de tratamento para a insuficiência e deficiência de vitamina d
NZ625712A (en) 2009-11-27 2016-02-26 Genzyme Corp An amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase
US11672809B2 (en) 2010-03-29 2023-06-13 Eirgen Pharma Ltd. Methods and compositions for reducing parathyroid levels
CN102525975B (zh) * 2011-12-14 2013-06-19 天津药物研究院药业有限责任公司 雷奈酸锶口腔崩解片及其制备方法
CN102626420B (zh) * 2012-04-13 2014-06-25 深圳大学 一种含有锶、钙和维生素d的混合制剂
ES2505716T3 (es) * 2013-01-21 2015-09-04 Galenicum Health S.L. Composiciones farmacéuticas que comprenden una sal de ácido
KR101847947B1 (ko) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 안정화되고 변형된 비타민 d 방출 제형
CN103142623B (zh) * 2013-03-21 2014-04-16 青岛正大海尔制药有限公司 骨化三醇和雷尼酸锶的混悬颗粒及其制备方法
US10220047B2 (en) 2014-08-07 2019-03-05 Opko Ireland Global Holdings, Ltd. Adjunctive therapy with 25-hydroxyvitamin D and articles therefor
EP3235822B1 (en) * 2014-12-19 2020-01-29 Nagasaki University Novel bisphosphonic acid derivative and application for same
WO2017182237A1 (en) 2016-03-28 2017-10-26 Opko Ireland Global Holdings, Limited Methods of vitamin d treatment
US10463636B2 (en) * 2016-09-30 2019-11-05 Deanna J. Nelson Pharmaceutical quality strontium L-lactate
IL270162B2 (en) * 2017-04-25 2025-07-01 Buck Inst Res Aging ?-ketoglutarate (akg) and (i) a vitamin a compound, or (ii) a vitamin d compound, for use in delaying onset or delaying progression of frailty
WO2019004984A2 (en) * 2017-05-29 2019-01-03 Biofarma Ilac Sanayi Ve Ticaret A.S. PHARMACEUTICAL FORMULATION COMPRISING CHOLECALCIFEROL
CN109276710A (zh) * 2018-11-23 2019-01-29 中国医学科学院药用植物研究所海南分所 一种增加骨密度的组合物及其制备方法和用途
CN112370429A (zh) * 2019-10-21 2021-02-19 广州富诺营养科技有限公司 一种直压型有机钙维生素d3咀嚼片及其制备方法
CN114452259A (zh) * 2021-07-28 2022-05-10 安徽旺盛添加剂有限公司 一种维生素d微囊钙片及其制备方法
WO2024246793A1 (en) * 2023-05-31 2024-12-05 Haleon Us Holdings Llc Active ingredient complex and method of making thereof
CN119055788A (zh) * 2023-05-31 2024-12-03 葛兰素史克消费保健(美国)控股有限责任公司 活性成分络合物及其制备方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS52130904A (en) * 1976-04-26 1977-11-02 Teijin Ltd Stabilization of vitamin d#
HU177586B (en) * 1978-12-19 1981-11-28 Chinoin Gyogyszer Es Vegyeszet New process for preparing stable inclusion complexes of vitamine d with cyclodextrin
US4727064A (en) * 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
FR2651497B1 (fr) 1989-09-01 1991-10-25 Adir Nouveaux sels de metaux bivalents de l'acide n, n-di (carboxymethyl)amino-2 cyano-3 carboxymethyl-4 carboxy-5 thiophene, leur procede de preparation et les compositions pharmaceutiques les renfermant.
CN1110275A (zh) * 1994-04-06 1995-10-18 福建省药品检验所 一种维生素D与羟丙基-β-环糊精的包合物
FR2749759B1 (fr) 1996-06-17 1999-11-26 Adir Utilisation de sels de strontium pour l'obtention de compositions pharmaceutiques destinees au traitement de l'arthrose
WO2001036490A2 (en) * 1999-11-12 2001-05-25 Pitha & Pitha Llc Crystalline mixtures of partial methyl ethers of beta-cyclodextrin and related compounds
WO2001048024A1 (en) * 1999-12-23 2001-07-05 Cerestar Holding B.V. Stabilized cyclodextrin complexes
JP2003268005A (ja) * 2002-03-14 2003-09-25 Medorekkusu:Kk 包接体の製造法
WO2004098618A2 (en) * 2003-05-07 2004-11-18 Osteologix A/S Strontium combinations for prophylaxis/treatment of cartilage and/or bone conditions
PL1622629T3 (pl) * 2003-05-07 2013-12-31 Osteologix As Kompozycja do kontrolowanego uwalniania zawierająca sól strontu
ES2275218T3 (es) 2003-05-07 2007-06-01 Osteologix A/S Sales de estroncio hidrosolubles para el tratamiento de afecciones de cartilagos y/o huesos.
JPWO2004106600A1 (ja) * 2003-05-30 2006-07-20 三井化学株式会社 人工毛髪用繊維
JP2007525472A (ja) * 2003-07-04 2007-09-06 ニコメド ダンマーク エイピーエス 経口使用のための副甲状腺ホルモン(pth)含有医薬組成物
WO2005123130A2 (en) * 2004-06-17 2005-12-29 Osteologix A/S Improved treatments of rheumatic and arthritic diseases comprising combinations of a 5-lipoxygenase inhibitor
CA2571449C (en) * 2004-06-25 2015-12-08 John Nikolaj Hvarre Christensen Compositions comprising strontium and vitamin d and uses thereof
CN101018586B (zh) * 2004-06-25 2014-08-27 莫克瓦洛Spf有限公司 含锶和维生素d的组合物及其用途
EP1865929A2 (en) * 2005-03-28 2007-12-19 Bioresponse, L.L.C. Diindolylmethane-based compositions and methods of use thereof for promoting oral mucosal and bone health
DE102005017775A1 (de) * 2005-04-13 2006-10-19 Schering Ag Komplexe aus Vitamin D-Verbindungen oder deren Analoga mit einem 5Z,7E,10(19)-Trien-System und methlierten Derivaten des ß-Cyclodextrins
US20070218111A1 (en) * 2006-03-16 2007-09-20 Western Holdings, Llc Strontium compositions for bones
CN1823764A (zh) * 2006-03-27 2006-08-30 重庆医药工业研究院有限责任公司 一种含有雷奈酸锶和维生素d药物组合物
FR2899895B1 (fr) 2006-04-12 2010-09-17 Servier Lab Nouveaux sels de strontium d'acides sulfoniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
KR100822133B1 (ko) * 2006-11-06 2008-04-15 한미약품 주식회사 비타민 d 또는 이의 유도체의 고체분산체 및비스포스포네이트를 포함하는, 골다공증 예방 또는 치료용복합제제

Also Published As

Publication number Publication date
AU2010241527A1 (en) 2011-06-16
UA105766C2 (uk) 2014-06-25
MX2010012566A (es) 2011-05-26
CO6280058A1 (es) 2011-05-20
ECSP10010622A (es) 2011-06-30
EA201001710A3 (ru) 2011-08-30
AP2010005490A0 (en) 2010-12-31
AU2010241527B2 (en) 2013-12-19
TW201200136A (en) 2012-01-01
MY158261A (en) 2016-09-30
AR079160A1 (es) 2011-12-28
MA32363B1 (fr) 2011-06-01
WO2011064474A1 (fr) 2011-06-03
KR101278935B1 (ko) 2013-06-28
GEP20135734B (en) 2013-01-25
US20110130370A1 (en) 2011-06-02
EA201001710A2 (ru) 2011-06-30
CN102078620A (zh) 2011-06-01
SV2010003744A (es) 2011-03-15
BRPI1004685A2 (pt) 2013-03-05
JP2011111458A (ja) 2011-06-09
FR2953139B1 (fr) 2012-04-13
CU20100230A7 (es) 2012-06-29
HN2010002518A (es) 2012-09-03
NZ589513A (en) 2012-06-29
UY33039A (es) 2011-04-29
CA2723119A1 (fr) 2011-05-27
KR20110059546A (ko) 2011-06-02
CA2723119C (fr) 2013-08-06
IL209348A0 (en) 2011-02-28
CL2010001260A1 (es) 2012-02-17
SG171542A1 (en) 2011-06-29
FR2953139A1 (fr) 2011-06-03
EA018460B1 (ru) 2013-08-30
EP2335704A1 (fr) 2011-06-22
ZA201008230B (en) 2011-07-27

Similar Documents

Publication Publication Date Title
PE20110407A1 (es) Composicion farmaceutica que comprende una sal de estroncio, vitamina d y una ciclodextrina
BR112012028291A2 (pt) composições farmacêuticas e métodos para sua produção
ES2721898T3 (es) Formulaciones estables para liofilizar partículas terapéuticas
BRPI0516830A (pt) composições de droga de liberação sustentada convenientemente implantáveis
AR094207A1 (es) Metodos de blanqueamiento dental, señales visualmente perceptibles y composiciones para ello
MX2010005542A (es) Producto para el cuidado oral y metodos de uso y fabricacion del mismo.
IL189600A (en) Pharmaceutical preparation containing nanostarticles containing Dostaxel in anhydrous state
EA201200551A1 (ru) Фармацевтическая композиция, фармацевтическая дозированная форма, способы их получения и применения для лечения
AR052925A1 (es) Forma cristalina betad del clorhidrato de ivabradina, un procedimiento para su preparacion y composiciones farmaceuticas que la contienen
MY155654A (en) Antibodies against human angiopoietin 2
AR085527A1 (es) Una composicon farmaceutica para tratar una enfermedad en la cavidad oral que comprende rebamipida
MX344238B (es) Compuestos de tetrazol y métodos para preparar y usar los mismos.
GT200600295A (es) Una formulacion solida de dosificacion farmaceutica
GT200900329A (es) Desodorante basado en propilenglicol/glicerina
EP2474522A4 (en) AGOME ELITE AND PHARMACEUTICAL COMPOSITIONS THEREOF
BRPI0914410A2 (pt) composição de polidesoxirribonucleotídeo injetável para o tratamento de doenças osteoarticulares.
CO6460707A2 (es) Películas que contienen una mayor concentración de zing
CL2008003699A1 (es) Nanopartícula que comprende pioglitazona y un polímero biocompatible, preparación farmacéutica que la contiene; stent (endoprótesis vascular) que la porta; y su uso en la profilaxis o tratamiento de enfermedades arterioescleróticas.
AR050717A1 (es) Composiciones farmaceuticas
ECSP10010576A (es) Formulaciones orales e inyectables de compuestos de tetraciclina
MX347858B (es) Composición antimicrobiana.
MX354483B (es) Composición antimicrobiana.
MX2012007234A (es) Nanocristales de monohidrato de calciprotiol.
AR076396A1 (es) Composicion para dar forma al cabello
NI200700031A (es) Formulaciones de ácido hidroxamico suberoilanilida y procedimientos para la producción de las mismas

Legal Events

Date Code Title Description
FC Refusal